Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders
NCT04978428Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Apr 2022
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in obsessive compulsive disorder (OCD), trichotillomania (TTM), Tourette syndrome (TS), hoarding disorder (HD), Excoriation Disorder, sponsored by University of Chicago. Started Apr 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
obsessive compulsive disorder (OCD)trichotillomania (TTM)Tourette syndrome (TS)hoarding disorder (HD)Excoriation Disorder
Beyond the preview
Go deeper on NCT04978428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978428.